HoyleCohen’s Summit Therapeutics SMMT Stock Holding History

HoyleCohen’s Portfolio SMMT Stock Details SMMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	$674K	Buy	86,408 +2,000	+2%	+$10.8K	0.05%	164
2024 Q1	$349K	Buy	84,408 +10,000	+13%	+$39.8K	0.03%	223
2023 Q4	$194K	Hold	74,408	–	–	0.02%	262
2023 Q3	$139K	Hold	74,408	–	–	0.01%	252
2023 Q2	$187K	Hold	74,408	–	–	0.02%	253
2023 Q1	$130K	Buy	74,408 +43,976	+145%	+$120K	0.01%	253
2022 Q4	$129K	Hold	30,432	–	–	0.01%	258
2022 Q3	$36K	Hold	30,432	–	–	﹤0.01%	255
2022 Q2	$30K	Buy	30,432 +15,000	+97%	+$21K	﹤0.01%	257
2022 Q1	$38K	Hold	15,432	–	–	﹤0.01%	271
2021 Q4	$42K	Hold	15,432	–	–	﹤0.01%	274
2021 Q3	$77K	Buy	15,432 +5,000	+48%	+$35.9K	0.01%	264
2021 Q2	$78	Buy	10,432 +73	+0.7%	+$479	0.01%	265
2021 Q1	$61K	Hold	10,359	–	–	0.01%	266
2020 Q4	$49K	Buy	+10,359	New	+$43.9K	0.01%	223

Other funds holding SMMT

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

HoyleCohen's SMMT Position: Q2 2024 in Review

HoyleCohen increased its Summit Therapeutics (SMMT) stake by 2.4% in Q2 2024, buying an estimated $10.8K and bringing the position to 86,408 shares worth $674K. The position accounts for 0.05% of the portfolio, ranked #164.

HoyleCohen first reported a position in SMMT in Q4 2020 and has held it in 15 quarters since. 123 funds tracked by Wall St. Rank hold SMMT as of Q2 2024.

HoyleCohen held 86,408 shares of Summit Therapeutics worth $674K as of Q2 2024.
HoyleCohen bought 2,000 Summit Therapeutics shares in Q2 2024, an estimated $10.8K.
Summit Therapeutics made up 0.05% of HoyleCohen's portfolio in Q2 2024, its #164 holding.
HoyleCohen first reported a position in Summit Therapeutics in Q4 2020 and has held it in 15 quarters since.
123 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2024.

Based on HoyleCohen's 13F filing for Q2 2024, filed 19 Jul 2024.